Company
ArrePath
New drug classes, discovered at machine speed
- Business model
- B2B
Claim, correct or request removal
Record updated 28 September 2026
About
Built to explore new chemical space and discover oral small molecules. ArrePath begins with the desired candidate profile, then deploys target-specific AI/ML workflows to evaluate novel chemistry while optimizing potency and developability in parallel.
Funding snapshot
- Total raised
- $3.7MSum of rounds, as of 2026-09-20Source (opens in a new tab)
- Latest round
- Grant, $3.7M2025-06-23
Funding rounds
- Grant
- $3.7M2025-06-23, Company stated
Loading relationship preview